Follow the nevus: The cost-utility of monitoring for growth of choroidal nevi

Alexander S. Barsam, Allister Gibbons, Andrew J. McClellan, J. William Harbour, William E. Smiddy

Research output: Contribution to journalArticle

Abstract

• AIM: To develop a model to evaluate the cost-utility of choroidal nevi monitoring recommendations with varying clinical risk factors. • METHODS: A Markov model was created to evaluate the cost-utility in cost per quality-adjusted life-year ($/QALY) for monitoring patients with choroidal nevus. This probabilistic model was applied both to a hypothetically monitored and unmonitored group of patients beginning at different ages and with varying clinical risk factors of the nevus. Duration of screening was modeled for the remainder of the patients�f life expectancy. Best available clinical data on the prevalence and incidence of choroidal nevi/melanoma, and relative risk of nevus transformation were combined with the initial and downstream costs of screening, downstream costs of melanoma-related mortality, and QALY saved by monitoring, to estimate the best monitoring regimen. Main outcome measures were average $/QALY saved by consensus recommended monitoring scenarios for the duration of a patient�fs remaining life expectancy in comparison with no follow-up, and the cost-utility of modified regimens. • RESULTS: The $/QALY of the recommended monitoring scenarios varied substantially based on nevus clinical risk factors, patient age, frequency of follow-up, and objective testing utilized. The $/QALY for the recommended monitoring scenario of a flat nevus without risk factors in a 60-yearold patient was $77 180. The $/QALY for monitoring a nevus with 3 clinical risk factors in a 60-year-old patient was $85 393. The $/QALY values for differently-aged patients were larger, and intermediate degrees of risk factors for nevus growth varied, depending largely upon the specifics of the modeled monitoring scenarios. • CONCLUSION: The average $/QALY of currently recommended monitoring scenarios fall within economically acceptable standards and could provide insight for formulating appropriate clinical strategies. Cost-utility could be enhanced by targeting higher risk groups and considering less frequent monitoring for the lower risk groups.

Original languageEnglish (US)
Pages (from-to)1456-1464
Number of pages9
JournalInternational Journal of Ophthalmology
Volume12
Issue number9
DOIs
StatePublished - Jan 1 2019

Fingerprint

Quality-Adjusted Life Years
Nevus
Costs and Cost Analysis
Growth
Life Expectancy
Nevi and Melanomas
Physiologic Monitoring
Statistical Models
Melanoma
Outcome Assessment (Health Care)
Mortality
Incidence

Keywords

  • Choroidal melanoma
  • Choroidal nevus
  • Cost-utility
  • Markov modeling
  • Screening

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Follow the nevus : The cost-utility of monitoring for growth of choroidal nevi. / Barsam, Alexander S.; Gibbons, Allister; McClellan, Andrew J.; Harbour, J. William; Smiddy, William E.

In: International Journal of Ophthalmology, Vol. 12, No. 9, 01.01.2019, p. 1456-1464.

Research output: Contribution to journalArticle

Barsam, Alexander S. ; Gibbons, Allister ; McClellan, Andrew J. ; Harbour, J. William ; Smiddy, William E. / Follow the nevus : The cost-utility of monitoring for growth of choroidal nevi. In: International Journal of Ophthalmology. 2019 ; Vol. 12, No. 9. pp. 1456-1464.
@article{7ba4e0c9cf784c008f6da5f623ccb48e,
title = "Follow the nevus: The cost-utility of monitoring for growth of choroidal nevi",
abstract = "• AIM: To develop a model to evaluate the cost-utility of choroidal nevi monitoring recommendations with varying clinical risk factors. • METHODS: A Markov model was created to evaluate the cost-utility in cost per quality-adjusted life-year ($/QALY) for monitoring patients with choroidal nevus. This probabilistic model was applied both to a hypothetically monitored and unmonitored group of patients beginning at different ages and with varying clinical risk factors of the nevus. Duration of screening was modeled for the remainder of the patients�f life expectancy. Best available clinical data on the prevalence and incidence of choroidal nevi/melanoma, and relative risk of nevus transformation were combined with the initial and downstream costs of screening, downstream costs of melanoma-related mortality, and QALY saved by monitoring, to estimate the best monitoring regimen. Main outcome measures were average $/QALY saved by consensus recommended monitoring scenarios for the duration of a patient�fs remaining life expectancy in comparison with no follow-up, and the cost-utility of modified regimens. • RESULTS: The $/QALY of the recommended monitoring scenarios varied substantially based on nevus clinical risk factors, patient age, frequency of follow-up, and objective testing utilized. The $/QALY for the recommended monitoring scenario of a flat nevus without risk factors in a 60-yearold patient was $77 180. The $/QALY for monitoring a nevus with 3 clinical risk factors in a 60-year-old patient was $85 393. The $/QALY values for differently-aged patients were larger, and intermediate degrees of risk factors for nevus growth varied, depending largely upon the specifics of the modeled monitoring scenarios. • CONCLUSION: The average $/QALY of currently recommended monitoring scenarios fall within economically acceptable standards and could provide insight for formulating appropriate clinical strategies. Cost-utility could be enhanced by targeting higher risk groups and considering less frequent monitoring for the lower risk groups.",
keywords = "Choroidal melanoma, Choroidal nevus, Cost-utility, Markov modeling, Screening",
author = "Barsam, {Alexander S.} and Allister Gibbons and McClellan, {Andrew J.} and Harbour, {J. William} and Smiddy, {William E.}",
year = "2019",
month = "1",
day = "1",
doi = "10.18240/ijo.2019.09.14",
language = "English (US)",
volume = "12",
pages = "1456--1464",
journal = "International Journal of Ophthalmology",
issn = "2222-3959",
publisher = "Press of International Journal of Ophthalmology",
number = "9",

}

TY - JOUR

T1 - Follow the nevus

T2 - The cost-utility of monitoring for growth of choroidal nevi

AU - Barsam, Alexander S.

AU - Gibbons, Allister

AU - McClellan, Andrew J.

AU - Harbour, J. William

AU - Smiddy, William E.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - • AIM: To develop a model to evaluate the cost-utility of choroidal nevi monitoring recommendations with varying clinical risk factors. • METHODS: A Markov model was created to evaluate the cost-utility in cost per quality-adjusted life-year ($/QALY) for monitoring patients with choroidal nevus. This probabilistic model was applied both to a hypothetically monitored and unmonitored group of patients beginning at different ages and with varying clinical risk factors of the nevus. Duration of screening was modeled for the remainder of the patients�f life expectancy. Best available clinical data on the prevalence and incidence of choroidal nevi/melanoma, and relative risk of nevus transformation were combined with the initial and downstream costs of screening, downstream costs of melanoma-related mortality, and QALY saved by monitoring, to estimate the best monitoring regimen. Main outcome measures were average $/QALY saved by consensus recommended monitoring scenarios for the duration of a patient�fs remaining life expectancy in comparison with no follow-up, and the cost-utility of modified regimens. • RESULTS: The $/QALY of the recommended monitoring scenarios varied substantially based on nevus clinical risk factors, patient age, frequency of follow-up, and objective testing utilized. The $/QALY for the recommended monitoring scenario of a flat nevus without risk factors in a 60-yearold patient was $77 180. The $/QALY for monitoring a nevus with 3 clinical risk factors in a 60-year-old patient was $85 393. The $/QALY values for differently-aged patients were larger, and intermediate degrees of risk factors for nevus growth varied, depending largely upon the specifics of the modeled monitoring scenarios. • CONCLUSION: The average $/QALY of currently recommended monitoring scenarios fall within economically acceptable standards and could provide insight for formulating appropriate clinical strategies. Cost-utility could be enhanced by targeting higher risk groups and considering less frequent monitoring for the lower risk groups.

AB - • AIM: To develop a model to evaluate the cost-utility of choroidal nevi monitoring recommendations with varying clinical risk factors. • METHODS: A Markov model was created to evaluate the cost-utility in cost per quality-adjusted life-year ($/QALY) for monitoring patients with choroidal nevus. This probabilistic model was applied both to a hypothetically monitored and unmonitored group of patients beginning at different ages and with varying clinical risk factors of the nevus. Duration of screening was modeled for the remainder of the patients�f life expectancy. Best available clinical data on the prevalence and incidence of choroidal nevi/melanoma, and relative risk of nevus transformation were combined with the initial and downstream costs of screening, downstream costs of melanoma-related mortality, and QALY saved by monitoring, to estimate the best monitoring regimen. Main outcome measures were average $/QALY saved by consensus recommended monitoring scenarios for the duration of a patient�fs remaining life expectancy in comparison with no follow-up, and the cost-utility of modified regimens. • RESULTS: The $/QALY of the recommended monitoring scenarios varied substantially based on nevus clinical risk factors, patient age, frequency of follow-up, and objective testing utilized. The $/QALY for the recommended monitoring scenario of a flat nevus without risk factors in a 60-yearold patient was $77 180. The $/QALY for monitoring a nevus with 3 clinical risk factors in a 60-year-old patient was $85 393. The $/QALY values for differently-aged patients were larger, and intermediate degrees of risk factors for nevus growth varied, depending largely upon the specifics of the modeled monitoring scenarios. • CONCLUSION: The average $/QALY of currently recommended monitoring scenarios fall within economically acceptable standards and could provide insight for formulating appropriate clinical strategies. Cost-utility could be enhanced by targeting higher risk groups and considering less frequent monitoring for the lower risk groups.

KW - Choroidal melanoma

KW - Choroidal nevus

KW - Cost-utility

KW - Markov modeling

KW - Screening

UR - http://www.scopus.com/inward/record.url?scp=85074093157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074093157&partnerID=8YFLogxK

U2 - 10.18240/ijo.2019.09.14

DO - 10.18240/ijo.2019.09.14

M3 - Article

AN - SCOPUS:85074093157

VL - 12

SP - 1456

EP - 1464

JO - International Journal of Ophthalmology

JF - International Journal of Ophthalmology

SN - 2222-3959

IS - 9

ER -